Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT02526797
Enrolling by invitation Observational

Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance

NCT02526797 · tracked via the Priya Life Science Denmark tracker
Sponsor
Herlev Hospital
Phase
Observational
Started
2013-01
Last updated
2026-09-16

Condition(s) studied

Prostatic Neoplasms

Study summary

To investigate whether multiparametric MRI (mp-MRI) in patients with low-risk prostate cancer can improve the selection of patients suitable for Active Surveillance and have a relevance in the ongoing monitoring.

Eligibility

Sex
MALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with low risk localized prostate cancer enrolled in active surveillance Exclusion Criteria: * Metastatic prostate cancer * No mp-MRI data present * Prostate cancer treatment * Known allergic reaction to Gadolinium-based MRI contrast agent * Prostate biopsy during the last 21 days * Impaired renal function with GFR \< 30 ml / min * pacemaker * Magnetic metal residues in the body * Claustrophobia * Psychiatric disorders * Age under 18 years

Primary outcome measure(s)

  • Changes in the treatment planning from active surveillance to active treatment based on mp-MRI — 3 months
    Observe changes in the detection-rate of significant prostate cancer using mp-MRI and mp-MRI targeted biopsies in men with newly diagnosed low risk prostate cancer enrolled i active surveillance. Mp-MRI is performed approximately 2½ month after the initial prostate biopsy.

Trial sites (1)

FacilityCityRegionStatus
Department of Urology, Herlev University Hospital Herlev Herlev Denmark

More Herlev Hospital trials in Denmark

Zinc Supplementation and Infections in Older Medical Patients Recruiting
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors Recruiting
Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance Enrolling by invitation
Zinc Supplementation and Inflammation in Older Medical Patients Recruiting
Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up Sessions Recruiting

Other trials for the same condition

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC) Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting
Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance Enrolling by invitation
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Active, not recruiting
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02526797 on ClinicalTrials.gov ↗ ← All trials in Denmark